Clinical Research Directory
Browse clinical research sites, groups, and studies.
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
Sponsor: Novartis Pharmaceuticals
Summary
The purpose of this study is to enhance the knowledge on asciminib treatment in a broader and real-life population by collecting additional data to characterize the treatment patterns of patients treated with asciminib, with a primary objective represented by maintenance on treatment at 12 months.
Official title: Scemblix® (Asciminib): Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML-CP in Real World Setting in France
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
201
Start Date
2024-03-06
Completion Date
2026-12-15
Last Updated
2026-02-06
Healthy Volunteers
No
Conditions
Interventions
Asciminib
There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
Locations (59)
Novartis Investigative Site
Angers, France, France
Novartis Investigative Site
Challes-les-Eaux, France, France
Novartis Investigative Site
Limoges, Haute Vienne, France
Novartis Investigative Site
Saint Priest Jarez, Pays de la Loire Region, France
Novartis Investigative Site
Aix-en-Provence, France
Novartis Investigative Site
Amiens, France
Novartis Investigative Site
Antibes, France
Novartis Investigative Site
Avignon, France
Novartis Investigative Site
Besançon, France
Novartis Investigative Site
Bobigny, France
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Brive-la-Gaillarde, France
Novartis Investigative Site
Caen, France
Novartis Investigative Site
Cagnes-sur-Mer, France
Novartis Investigative Site
Cannes, France
Novartis Investigative Site
Castelnau-le-Lez, France
Novartis Investigative Site
Cesson-Sévigné, France
Novartis Investigative Site
Chambéry, France
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
Corbeil-Essonnes, France
Novartis Investigative Site
Dunkirk, France
Novartis Investigative Site
Essey-lès-Nancy, France
Novartis Investigative Site
Grenoble, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Le Mans, France
Novartis Investigative Site
Lens, France
Novartis Investigative Site
Libourne, France
Novartis Investigative Site
Lorient, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Mulhouse, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Nevers, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Nîmes, France
Novartis Investigative Site
Orléans, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Perpignan, France
Novartis Investigative Site
Périgueux, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Poitiers, France
Novartis Investigative Site
Quimper, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Roubaix, France
Novartis Investigative Site
St-Malo, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Tarbes, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Tours, France
Novartis Investigative Site
Trévenans, France
Novartis Investigative Site
Troyes, France
Novartis Investigative Site
Valence, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Vesoul, France